Genentech Articles
Stock Commentary - New York
9 August 2004
Biogen Idec closes 2nd-qtr above expectations
9 August 2004
Tarceva NDA filing completed in USA
9 August 2004
Roche offer to New Zealand research
2 August 2004
Agensys signs accord with Genentech
2 August 2004
Roche's net income doubles for 1st-half
26 July 2004
Phenomix signs deal with Genentech
19 July 2004
Stock Commentary - New York
19 July 2004
Stock Commentary - Europe
19 July 2004
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Xolair being evaluated in peanut allergy
19 July 2004
Four new senior appointments at Genentech
12 July 2004
Novartis files for EU approval of Xolair
12 July 2004
New use in EU for Roche's Herceptin
28 June 2004
Stock Commentary - New York
21 June 2004
Stock Commentary - Europe
21 June 2004
OSI and Genentech sign agreements for Tarceva
21 June 2004
Is the use of a placebo ethical in cancer trials?
21 June 2004
Stock Commentary - New York
14 June 2004
Tarceva shows promise for NSCLC
14 June 2004
Xoma's 1st-qtr 2004 net loss widens 54%
24 May 2004
New data for Serono's Raptiva; CLEAR study
10 May 2004
Stock Commentary - New York
3 May 2004
Stock Commentary - Europe
3 May 2004
Roche 1st-qtr beats expectations
26 April 2004
Serono's 1st-qtr income rockets 76.4%
26 April 2004
Cancer drug developments and attitudes in Japan
26 April 2004
Genentech's sales up 28% for 1st-qtr 2004
19 April 2004
Stock Commentary - New York
29 March 2004
Serono's Raptiva gets first OK in Europe
22 March 2004
McClellan at CMS "a boon for biotech"
22 March 2004
Celltech sees sales rise 6% in 2003
22 March 2004
Organizational changes at Genentech
15 March 2004
Stock Commentary - New York
8 March 2004
Stock Commentary - Europe
8 March 2004
Merger costs Biogen Idec a $991M loss
8 March 2004
UPDATE: ImClone's Erbitux cleared by FDA
23 February 2004
Stock Commentary - New York
2 February 2004
OSI/Genentech/Roche's Tarceva filed in USA
2 February 2004
Senior appointments at Genentech
26 January 2004
Stock Commentary - New York
26 January 2004
MabThera EU filing for first-line indolent NHL
26 January 2004
Applied Imaging gets FDA nod for breast cancer test
26 January 2004
New Chemical Entities in 2003
19 January 2004
Tokyo pharma stocks - week to Jan 5
5 January 2004
Array surges on news of Genentech deal
5 January 2004
Herceptin offers no benefit in lung cancer
30 November 2003
Roche signs Japanese deal with Chugai
22 December 2003
New data for Rituxan/ MabThera at ASH
15 December 2003
Roche files Avastin for European approval
15 December 2003
Stock Commentary - New York
8 December 2003
Genentech and Protein Design resolve patent dispute
8 December 2003
Genentech gains priority review for Avastin BLA
8 December 2003
Rituximab meets goal in NHL trial
24 November 2003
Serono beats expectations with 3rd-qtr 2003 net income up 48%
3 November 2003
New wave of drugs offer hope in treatment of colon cancer
3 November 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Stock Commentary - New York
20 October 2003
Rituxan drives IDEC upwards in 3rd quarter
20 October 2003
Commercial and research promotions at Genentech
13 October 2003
Ph III Tarceva studies disappoint
6 October 2003
Herceptin combi helps breast cancer survival
6 October 2003
Genentech files BLA with FDA for Avastin
6 October 2003
Stock Commentary - New York
29 September 2003
Stock Commentary - Europe
22 September 2003
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
